Recent News for BBIO - BridgeBio Pharma, Inc.

Date Title
Jan 14 BridgeBio Pharma (BBIO) Investor Presentation - Slideshow
Jan 13 BridgeBio up 8% on pipeline expansion
Jan 13 BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source
Jan 10 BridgeBio teams up with Catalent in gene therapy development/manufacturing
Jan 10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity
Jan 8 PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma
Jan 6 BridgeBio nabs accelerated review in U.S. for infigratinib for bile duct cancer
Jan 6 BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma
Dec 24 The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
Dec 21 Stocks To Watch: Amazon To Star On Boxing Day
Dec 20 Key events next week - healthcare
Dec 19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference
Dec 18 BridgeBio inks BBP-870 commercialization deal in Israel
Dec 18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A
Dec 17 The 5 top performing IPOs of 2019
Dec 16 BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member
Dec 13 BridgeBio Pharma, Inc. (BBIO): Are Hedge Funds Right About This Stock?
Dec 10 The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
Dec 9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs
Dec 3 BridgeBio initiates rolling submission of U.S. application for BBP-870 in MoCD Type A
Dec 3 BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A
Dec 2 PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
Nov 27 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Nov 22 The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
Nov 18 Eidos up 13% on sustained benefit of AG10 in ATTR-CM

Back to the Main BBIO Page...